The IL 23 inhibitors, effective in inflammatory conditions such as psoriasis, could be repurposed to treat patients with bone and soft tissue sarcoma. Researchers from the Garvan Institute have recently demonstrated that IL 23, regulated by the glutamate metabotropic receptor 4 (GRM4), is central to the development of osteosarcoma. The findings, published in Cancer Discovery, ...
Psoriasis drugs on trial soon for sarcoma
By Mardi Chapman
15 Oct 2019